ClinicalTrials.gg

Attention Deficit Disorder with Hyperactivity clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,818 studies for Attention Deficit Disorder with Hyperactivity across more than 10 countries. 295 are recruiting or about to start. 1,562 of them are mainly about Attention Deficit Disorder with Hyperactivity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,827 studies for Attention Deficit Disorder with Hyperactivity. How that becomes 1,817 here

This page counts the studies the registry files under Attention Deficit Disorder with Hyperactivity, and those it files under no condition that list Attention Deficit Disorder with Hyperactivitythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 1,827Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2List Attention Deficit Disorder with Hyperactivity as a condition, but the registry did not file them under itMost often written as “Attention Deficit Disorder With Hyperactivity Disease” (1) and “ADHD - Combined Type” (1). The registry filed them under other conditions only, most often Hyperkinesis (1) and Attention Deficit and Disruptive Behavior Disorders (1).
  3. −20Match it another way16 name it in the title and 4 by a synonym or other text the search reads.
  4. 1,805Counted here and found by its search8 of them list Attention Deficit Disorder with Hyperactivity in their own words; the registry filed them under no condition.
  5. +12
    Counted here, but its search does not find them
  6. 1,817The count on this page

Status

Completed
1,168
Status unknown
201
Recruiting
201
Not yet recruiting
72
Terminated
64
Active, not recruiting
45

Phase

Phase 4
231
Phase 3
228
Phase 2
176
Phase 1
79
Early Phase 1
18

Where

United States
807
Canada
85
Israel
85
France
82
Taiwan
73
Germany
63

Who develops what

Add Attention Deficit Disorder with Hyperactivity to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 7 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Alkermes, Axsome Therapeutics and Boehringer Ingelheim here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
atomoxetineEarlier only
Evidence
  • NCT04085172 · Takeda · Phase 4 · comparator · “Atomoxetine hydrochloride” · registered Sep 2019
  • NCT03324581 · Otsuka Holdings Co., Ltd. · Phase 2 · comparator · “Atomoxetine” · registered Oct 2017
  • NCT01244490 · Takeda · Phase 3 · comparator · “Atomoxetine Hydrochloride” · registered Nov 2010
  • NCT01106430 · Takeda · Phase 3 · comparator · “Atomoxetine Hydrochloride” · registered Apr 2010
  • NCT00880217 · Johnson & Johnson · Phase 2 · comparator · “Atomoxetine 80 mg/d” · registered Apr 2009
Eli Lilly and Company93% of its industry studiesUS: off-patent, 8 generics marketed00 studies
MethylphenidateEarlier only
Evidence
  • NCT04507204 · Knoa Pharma · Phase 4 · comparator · “Concerta” · registered Jul 2020
  • NCT02778360 · mensia technologies sa · Phase 2 · comparator · “Methylphenidate MPH” · registered May 2016
  • NCT02168127 · Knoa Pharma · Phase 3 · background · “Drug: PRC-063” · registered Jun 2014
  • NCT01552902 · Takeda · Phase 4 · comparator · “Methylphenidate Hydrochloride” · registered Mar 2012
  • NCT01552915 · Takeda · Phase 4 · comparator · “Methylphenidate Hydrochloride” · registered Mar 2012
Johnson & Johnson32% of its industry studiesUS: off-patent, 36 generics marketedEU: Neuraxpharm Pharmaceuticals S.L. (EMA 2025)00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
centanafadine hydrochlorideApproved: US 2026☆ Track5 live phase-3 studies: NCT07759154, NCT06926829, NCT06931080Otsuka Holdings Co., Ltd.
AK-D101☆ Track1 live phase-3 study: NCT07678827Lotus Pharmaceutical Co., Ltd.
solriamfetolApproved: US 2019 · EU 2020☆ Track3 live phase-3 studies: NCT07717879, NCT07717892, NCT07773883Axsome Therapeutics, Inc.

The 3 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 27 May 2027 est.centanafadine hydrochloride · Otsuka Holdings Co., Ltd. · Phase 3 main aimNCT07759154 A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation — primary endpoint: Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score · 80 enrolled
  • Jul 2027 est.ALKS 7290 · Alkermes, Inc. · Phase 2 main aimNCT07755410 A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) — primary endpoint: Change from Baseline to Week 4 in Attention Deficit Disorder Investigator Symptom Rating Scale (AISRS) total score · 312 enrolled
  • Aug 2027 est.centanafadine hydrochloride · Otsuka Holdings Co., Ltd. · Phase 3 main aimNCT07087327 A Long-term Trial of EB-1020 in Pediatric Patients With ADHD — primary endpoint: Number of Patients Experiencing Treatment-Emergent Adverse Events (TEAEs) · 180 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Attention Deficit Disorder with Hyperactivity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Stimulants 21 open · Antipsychotics 21

Coming up

97studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger. 141 (70%) take children under 18. 7 (3%) are for women only and 1 (<1%) for men only; 55 (27%) take healthy volunteers.

Recruiting studies that take each age, of 201
AgeWomenMen
10105 (52%)103 (51%)
1898 (49%)92 (46%)
3067 (33%)60 (30%)
4064 (32%)58 (29%)
5060 (30%)55 (27%)
6547 (23%)43 (21%)
7535 (17%)31 (15%)
8530 (15%)26 (13%)

Across all 1,818 studies, recruiting or not: 90% stop at 75 or younger and 89% at 65; 71% take children; 1% are for women only and 2% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Attention Deficit Disorder with Hyperactivity studies take

Of 80 phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 19 mo2–26 · 35 studies2 mo1–7 · 21 studies—
Phase 215 mo5–34 · 40 studies10 mo4–14 · 24 studies—
Phase 314 mo7–32 · 80 studies12 mo6–19 · 66 studies—
Phase 438 mo18–70 · 62 studies—59 mo37–81 · 44 studies
Interventional, no phase23 mo11–41 · 511 studies12 mo7–17 · 31 studies24 mo11–43 · 480 studies
Observational35 mo18–68 · 96 studies—35 mo18–69 · 86 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,818. Browse all 1,818 → or search them.